Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo
The neurotrophin receptors TrkA (NGF receptor) and TrkC (NT-3 receptor) have been shown to be important in staging disease and predicting progression and drug response for various neoplasias such as neuroblastoma, medulloblastoma and prostate cancer. Less is known about the role of the p75 neurotrop...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2010-05, Vol.65 (6), p.1047-1056 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1056 |
|---|---|
| container_issue | 6 |
| container_start_page | 1047 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 65 |
| creator | Bassili, Muriel Birman, Elena Schor, Nina F. Saragovi, H. Uri |
| description | The neurotrophin receptors TrkA (NGF receptor) and TrkC (NT-3 receptor) have been shown to be important in staging disease and predicting progression and drug response for various neoplasias such as neuroblastoma, medulloblastoma and prostate cancer. Less is known about the role of the p75 neurotrophin receptor in cancer, but it influences metastatic potential in glioblastoma. To determine the effect of each neurotrophin receptor or co-receptor expression in tumorigenesis, we examined PC12 pheochromocytomas. PC12 wild type (TrkA
+
, p75
++
) were compared to three PC12-derived cell lines expressing varying levels of TrkA or TrkC and/or p75. Growth rates, tumorigenic potential ex vivo and in vivo, and chemotherapeutic drug response profiles differed depending on the neurotrophin receptor phenotype. The ability of neurotrophins to rescue cells from doxorubicin or cisplatin induced cell death also varied depending on phenotype. Thus, unique neurotrophin receptor tumor profiles may determine tumor aggressiveness and chemoresistance. This work may help to develop tailored therapies for specific tumor phenotypes by combining traditional chemotherapy with neurotrophin receptor modulators. |
| doi_str_mv | 10.1007/s00280-009-1110-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4315186</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1986126551</sourcerecordid><originalsourceid>FETCH-LOGICAL-c530t-91c95cf7e96d24b85ce70b3c6cc9e62a5471ebbf9e46a08f3d44f0054115f6de3</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhi0EokvhB3BBFhLiFBjHdpxckKryKVXiUs6W44x3XbL21k5Wy7_H6a5aQOJkj-eZd2b8EvKSwTsGoN5ngLqFCqCrGGNQHR6RFRO8rqAV_DFZAReikgrEGXmW8w0ACMb5U3LGOgWs4WJFbj965zBhmLwZaYojZhodvU4_qQkD3SlJA84pTinuNj7QhBZ3U0yZlmCatzH5NQbMPt_xdoPlaQknEyxSPNC938e7XClY7s_JE2fGjC9O5zn58fnT9eXX6ur7l2-XF1eVlRymqmO2k9Yp7JqhFn0rLSrouW2s7bCpjRSKYd-7DkVjoHV8EMIBSMGYdM2A_Jx8OOru5n6Lgy0rJjPqXfJbk37paLz-OxP8Rq_jXgvOJGubIvD2JJDi7Yx50lufLY6jCRjnrJWQ3WIAL-Trf8ibOKdQttM146KtmWIFYkfIpphzQnc_CgO92KmPdupip17s1IdS8-rPHR4qTv4V4M0JMNma0aXy6z7fc3UtlWzFwtVHLpdUWGN6mPD_3X8D5DC6hQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213482171</pqid></control><display><type>article</type><title>Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo</title><source>MEDLINE</source><source>Springer Nature</source><creator>Bassili, Muriel ; Birman, Elena ; Schor, Nina F. ; Saragovi, H. Uri</creator><creatorcontrib>Bassili, Muriel ; Birman, Elena ; Schor, Nina F. ; Saragovi, H. Uri</creatorcontrib><description>The neurotrophin receptors TrkA (NGF receptor) and TrkC (NT-3 receptor) have been shown to be important in staging disease and predicting progression and drug response for various neoplasias such as neuroblastoma, medulloblastoma and prostate cancer. Less is known about the role of the p75 neurotrophin receptor in cancer, but it influences metastatic potential in glioblastoma. To determine the effect of each neurotrophin receptor or co-receptor expression in tumorigenesis, we examined PC12 pheochromocytomas. PC12 wild type (TrkA
+
, p75
++
) were compared to three PC12-derived cell lines expressing varying levels of TrkA or TrkC and/or p75. Growth rates, tumorigenic potential ex vivo and in vivo, and chemotherapeutic drug response profiles differed depending on the neurotrophin receptor phenotype. The ability of neurotrophins to rescue cells from doxorubicin or cisplatin induced cell death also varied depending on phenotype. Thus, unique neurotrophin receptor tumor profiles may determine tumor aggressiveness and chemoresistance. This work may help to develop tailored therapies for specific tumor phenotypes by combining traditional chemotherapy with neurotrophin receptor modulators.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-009-1110-x</identifier><identifier>PMID: 19701634</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Animals ; Antineoplastic agents ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Apoptosis - drug effects ; Biological and medical sciences ; Cancer Research ; Cell Proliferation - drug effects ; Cell Survival - drug effects ; Cell Survival - genetics ; Cisplatin - pharmacology ; Dose-Response Relationship, Drug ; Doxorubicin - pharmacology ; Drug Resistance, Neoplasm - genetics ; Female ; Medical sciences ; Medicine ; Medicine & Public Health ; Mice ; Mice, Nude ; Mutation ; Neoplasms, Experimental - genetics ; Neoplasms, Experimental - pathology ; Neoplasms, Experimental - prevention & control ; Oncology ; Original Article ; PC12 Cells ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Rats ; Receptor, Nerve Growth Factor - genetics ; Receptor, Nerve Growth Factor - physiology ; Receptor, trkA - genetics ; Receptor, trkA - physiology ; Time Factors ; Tumor Burden - drug effects ; Xenograft Model Antitumor Assays - methods</subject><ispartof>Cancer chemotherapy and pharmacology, 2010-05, Vol.65 (6), p.1047-1056</ispartof><rights>Springer-Verlag 2009</rights><rights>2015 INIST-CNRS</rights><rights>Springer-Verlag 2010</rights><rights>Springer-Verlag 2009 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c530t-91c95cf7e96d24b85ce70b3c6cc9e62a5471ebbf9e46a08f3d44f0054115f6de3</citedby><cites>FETCH-LOGICAL-c530t-91c95cf7e96d24b85ce70b3c6cc9e62a5471ebbf9e46a08f3d44f0054115f6de3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-009-1110-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-009-1110-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22575844$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19701634$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bassili, Muriel</creatorcontrib><creatorcontrib>Birman, Elena</creatorcontrib><creatorcontrib>Schor, Nina F.</creatorcontrib><creatorcontrib>Saragovi, H. Uri</creatorcontrib><title>Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>The neurotrophin receptors TrkA (NGF receptor) and TrkC (NT-3 receptor) have been shown to be important in staging disease and predicting progression and drug response for various neoplasias such as neuroblastoma, medulloblastoma and prostate cancer. Less is known about the role of the p75 neurotrophin receptor in cancer, but it influences metastatic potential in glioblastoma. To determine the effect of each neurotrophin receptor or co-receptor expression in tumorigenesis, we examined PC12 pheochromocytomas. PC12 wild type (TrkA
+
, p75
++
) were compared to three PC12-derived cell lines expressing varying levels of TrkA or TrkC and/or p75. Growth rates, tumorigenic potential ex vivo and in vivo, and chemotherapeutic drug response profiles differed depending on the neurotrophin receptor phenotype. The ability of neurotrophins to rescue cells from doxorubicin or cisplatin induced cell death also varied depending on phenotype. Thus, unique neurotrophin receptor tumor profiles may determine tumor aggressiveness and chemoresistance. This work may help to develop tailored therapies for specific tumor phenotypes by combining traditional chemotherapy with neurotrophin receptor modulators.</description><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>Cancer Research</subject><subject>Cell Proliferation - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Cell Survival - genetics</subject><subject>Cisplatin - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Doxorubicin - pharmacology</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Female</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Mutation</subject><subject>Neoplasms, Experimental - genetics</subject><subject>Neoplasms, Experimental - pathology</subject><subject>Neoplasms, Experimental - prevention & control</subject><subject>Oncology</subject><subject>Original Article</subject><subject>PC12 Cells</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Rats</subject><subject>Receptor, Nerve Growth Factor - genetics</subject><subject>Receptor, Nerve Growth Factor - physiology</subject><subject>Receptor, trkA - genetics</subject><subject>Receptor, trkA - physiology</subject><subject>Time Factors</subject><subject>Tumor Burden - drug effects</subject><subject>Xenograft Model Antitumor Assays - methods</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kU1v1DAQhi0EokvhB3BBFhLiFBjHdpxckKryKVXiUs6W44x3XbL21k5Wy7_H6a5aQOJkj-eZd2b8EvKSwTsGoN5ngLqFCqCrGGNQHR6RFRO8rqAV_DFZAReikgrEGXmW8w0ACMb5U3LGOgWs4WJFbj965zBhmLwZaYojZhodvU4_qQkD3SlJA84pTinuNj7QhBZ3U0yZlmCatzH5NQbMPt_xdoPlaQknEyxSPNC938e7XClY7s_JE2fGjC9O5zn58fnT9eXX6ur7l2-XF1eVlRymqmO2k9Yp7JqhFn0rLSrouW2s7bCpjRSKYd-7DkVjoHV8EMIBSMGYdM2A_Jx8OOru5n6Lgy0rJjPqXfJbk37paLz-OxP8Rq_jXgvOJGubIvD2JJDi7Yx50lufLY6jCRjnrJWQ3WIAL-Trf8ibOKdQttM146KtmWIFYkfIpphzQnc_CgO92KmPdupip17s1IdS8-rPHR4qTv4V4M0JMNma0aXy6z7fc3UtlWzFwtVHLpdUWGN6mPD_3X8D5DC6hQ</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>Bassili, Muriel</creator><creator>Birman, Elena</creator><creator>Schor, Nina F.</creator><creator>Saragovi, H. Uri</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7TK</scope><scope>5PM</scope></search><sort><creationdate>20100501</creationdate><title>Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo</title><author>Bassili, Muriel ; Birman, Elena ; Schor, Nina F. ; Saragovi, H. Uri</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c530t-91c95cf7e96d24b85ce70b3c6cc9e62a5471ebbf9e46a08f3d44f0054115f6de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>Cancer Research</topic><topic>Cell Proliferation - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Cell Survival - genetics</topic><topic>Cisplatin - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Doxorubicin - pharmacology</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Female</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Mutation</topic><topic>Neoplasms, Experimental - genetics</topic><topic>Neoplasms, Experimental - pathology</topic><topic>Neoplasms, Experimental - prevention & control</topic><topic>Oncology</topic><topic>Original Article</topic><topic>PC12 Cells</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Rats</topic><topic>Receptor, Nerve Growth Factor - genetics</topic><topic>Receptor, Nerve Growth Factor - physiology</topic><topic>Receptor, trkA - genetics</topic><topic>Receptor, trkA - physiology</topic><topic>Time Factors</topic><topic>Tumor Burden - drug effects</topic><topic>Xenograft Model Antitumor Assays - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bassili, Muriel</creatorcontrib><creatorcontrib>Birman, Elena</creatorcontrib><creatorcontrib>Schor, Nina F.</creatorcontrib><creatorcontrib>Saragovi, H. Uri</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Proquest Health and Medical Complete</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Neurosciences Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bassili, Muriel</au><au>Birman, Elena</au><au>Schor, Nina F.</au><au>Saragovi, H. Uri</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2010-05-01</date><risdate>2010</risdate><volume>65</volume><issue>6</issue><spage>1047</spage><epage>1056</epage><pages>1047-1056</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>The neurotrophin receptors TrkA (NGF receptor) and TrkC (NT-3 receptor) have been shown to be important in staging disease and predicting progression and drug response for various neoplasias such as neuroblastoma, medulloblastoma and prostate cancer. Less is known about the role of the p75 neurotrophin receptor in cancer, but it influences metastatic potential in glioblastoma. To determine the effect of each neurotrophin receptor or co-receptor expression in tumorigenesis, we examined PC12 pheochromocytomas. PC12 wild type (TrkA
+
, p75
++
) were compared to three PC12-derived cell lines expressing varying levels of TrkA or TrkC and/or p75. Growth rates, tumorigenic potential ex vivo and in vivo, and chemotherapeutic drug response profiles differed depending on the neurotrophin receptor phenotype. The ability of neurotrophins to rescue cells from doxorubicin or cisplatin induced cell death also varied depending on phenotype. Thus, unique neurotrophin receptor tumor profiles may determine tumor aggressiveness and chemoresistance. This work may help to develop tailored therapies for specific tumor phenotypes by combining traditional chemotherapy with neurotrophin receptor modulators.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>19701634</pmid><doi>10.1007/s00280-009-1110-x</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2010-05, Vol.65 (6), p.1047-1056 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4315186 |
| source | MEDLINE; Springer Nature |
| subjects | Animals Antineoplastic agents Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Apoptosis - drug effects Biological and medical sciences Cancer Research Cell Proliferation - drug effects Cell Survival - drug effects Cell Survival - genetics Cisplatin - pharmacology Dose-Response Relationship, Drug Doxorubicin - pharmacology Drug Resistance, Neoplasm - genetics Female Medical sciences Medicine Medicine & Public Health Mice Mice, Nude Mutation Neoplasms, Experimental - genetics Neoplasms, Experimental - pathology Neoplasms, Experimental - prevention & control Oncology Original Article PC12 Cells Pharmacology. Drug treatments Pharmacology/Toxicology Rats Receptor, Nerve Growth Factor - genetics Receptor, Nerve Growth Factor - physiology Receptor, trkA - genetics Receptor, trkA - physiology Time Factors Tumor Burden - drug effects Xenograft Model Antitumor Assays - methods |
| title | Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T15%3A22%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20roles%20of%20Trk%20and%20p75%20neurotrophin%20receptors%20in%20tumorigenesis%20and%20chemoresistance%20ex%20vivo%20and%20in%20vivo&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Bassili,%20Muriel&rft.date=2010-05-01&rft.volume=65&rft.issue=6&rft.spage=1047&rft.epage=1056&rft.pages=1047-1056&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/s00280-009-1110-x&rft_dat=%3Cproquest_pubme%3E1986126551%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213482171&rft_id=info:pmid/19701634&rfr_iscdi=true |